-transparent.png){kind=logo}
Substance P is an important neuromediator in spinal synaptic transmission, particularly in processing nociceptive afferent information. The effects of substance P are mediated by activation of the neurokinin 1 receptor. Evidence has suggested that excitatory amino acids such as glutamate, and prostaglandins including prostaglandin E2 are involved in the enhanced spinal excitability and hyperalgesia produced by spinal substance P. In the present study, we have demonstrated that intrathecal injection of substance P (20 nmol) in rats chronically implanted with intrathecal dialysis catheters induced a decrease in thermal paw withdrawal latency (before: 10.4+/-0.3 s; after 7.6+/-0.6 s), which was accompanied by an increase in prostaglandin E2 (362+/-37% of baseline), glutamate (267+/-84%) and taurine (279+/-57%), but not glycine, glutamine, serine or asparagine. Intrathecal injection of artificial cerebrospinal fluid had no effect upon the behavior or release. Substance P-induced thermal hyperalgesia and prostaglandin E2 release were significantly attenuated by a selective neurokinin 1 receptor antagonist RP67580, but not by an enantiomer RP68651. However, substance P-induced release of glutamate and taurine was not reduced by treatment with RP67580. SR140333, another neurokinin 1 receptor antagonist, displayed the same effects as RP67580 (i.e. block of thermal hyperalgesia and prostaglandin E2 release, but not release of amino acids). These results provide direct evidence suggesting that the spinal substance P-induced thermal hyperalgesia is mediated by an increase in spinal prostaglandin E2 via activation of the neurokinin 1 receptor. These findings define an important linkage between small afferents, sensory neurotransmitter release and spinal prostanoids in the cascade of spinally-mediated hyperalgesia. The evoked release of glutamate is apparently not a result of activation of neurokinin 1 receptors. Accordingly, consistent with other pharmacological data, acute spinal glutamate release does not contribute to the hyperalgesia induced by activation of spinal neurokinin 1 receptors.
X Y Hua, and
P Chen, and
M Marsala, and
T L Yaksh
September 2003,
The journal of pain,
X Y Hua, and
P Chen, and
M Marsala, and
T L Yaksh
September 2001,
Acta pharmacologica Sinica,
X Y Hua, and
P Chen, and
M Marsala, and
T L Yaksh
January 1998,
Japanese journal of pharmacology,
X Y Hua, and
P Chen, and
M Marsala, and
T L Yaksh
January 1996,
Neuroscience,
X Y Hua, and
P Chen, and
M Marsala, and
T L Yaksh
January 2006,
The Journal of pharmacology and experimental therapeutics,
X Y Hua, and
P Chen, and
M Marsala, and
T L Yaksh
September 1991,
Neuroscience research,
X Y Hua, and
P Chen, and
M Marsala, and
T L Yaksh
January 2003,
Neuroscience,
X Y Hua, and
P Chen, and
M Marsala, and
T L Yaksh
November 1998,
The American journal of physiology,
X Y Hua, and
P Chen, and
M Marsala, and
T L Yaksh
April 2000,
The Journal of pharmacy and pharmacology,
X Y Hua, and
P Chen, and
M Marsala, and
T L Yaksh
June 1994,
Pain,
